213 related articles for article (PubMed ID: 14710235)
21. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
Magné N; Fischel JL; Tiffon C; Formento P; Dubreuil A; Renée N; Formento JL; Francoual M; Ciccolini J; Etienne MC; Milano G
Br J Cancer; 2003 Aug; 89(3):585-92. PubMed ID: 12888834
[TBL] [Abstract][Full Text] [Related]
23. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Shien T; Doihara H; Hara H; Takahashi H; Yoshitomi S; Taira N; Ishibe Y; Teramoto J; Aoe M; Shimizu N
Breast Cancer; 2004; 11(4):367-73. PubMed ID: 15604992
[TBL] [Abstract][Full Text] [Related]
24. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.
Maiello MR; D'Alessio A; De Luca A; Carotenuto A; Rachiglio AM; Napolitano M; Cito L; Guzzo A; Normanno N
Breast Cancer Res Treat; 2007 May; 102(3):275-82. PubMed ID: 17004112
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Vicentini C; Festuccia C; Gravina GL; Angelucci A; Marronaro A; Bologna M
J Cancer Res Clin Oncol; 2003 Mar; 129(3):165-74. PubMed ID: 12712332
[TBL] [Abstract][Full Text] [Related]
26. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
28. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
Jones HE; Goddard L; Gee JM; Hiscox S; Rubini M; Barrow D; Knowlden JM; Williams S; Wakeling AE; Nicholson RI
Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453
[TBL] [Abstract][Full Text] [Related]
29. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
[TBL] [Abstract][Full Text] [Related]
30. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
DeFriend DJ; Anderson E; Bell J; Wilks DP; West CM; Mansel RE; Howell A
Br J Cancer; 1994 Aug; 70(2):204-11. PubMed ID: 8054267
[TBL] [Abstract][Full Text] [Related]
31. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
Magné N; Fischel JL; Dubreuil A; Formento P; Poupon MF; Laurent-Puig P; Milano G
Br J Cancer; 2002 May; 86(9):1518-23. PubMed ID: 11986789
[TBL] [Abstract][Full Text] [Related]
32. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
[TBL] [Abstract][Full Text] [Related]
34. Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.
Shen H; Liu J; Wang R; Qian X; Xu R; Xu T; Li Q; Wang L; Shi Z; Zheng J; Chen Q; Shu Y
Biomed Pharmacother; 2014 Apr; 68(3):307-13. PubMed ID: 24268810
[TBL] [Abstract][Full Text] [Related]
35. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
Xu R; Shen H; Guo R; Sun J; Gao W; Shu Y
Biomed Pharmacother; 2012 Jul; 66(5):384-9. PubMed ID: 22560634
[TBL] [Abstract][Full Text] [Related]
36. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
37. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
Filardo EJ; Quinn JA; Bland KI; Frackelton AR
Mol Endocrinol; 2000 Oct; 14(10):1649-60. PubMed ID: 11043579
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
[TBL] [Abstract][Full Text] [Related]
39. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Massarweh S; Tham YL; Huang J; Sexton K; Weiss H; Tsimelzon A; Beyer A; Rimawi M; Cai WY; Hilsenbeck S; Fuqua S; Elledge R
Breast Cancer Res Treat; 2011 Oct; 129(3):819-27. PubMed ID: 21792626
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Carlson RW; O'Neill A; Vidaurre T; Gomez HL; Badve SS; Sledge GW
Breast Cancer Res Treat; 2012 Jun; 133(3):1049-56. PubMed ID: 22418699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]